

10 Jul 2017 | Analysis

Podcast: Big Pharma Licensing Trends

by **Amanda Micklus**

Big pharma comprises a smaller proportion of the deals market than mid-size and smaller biopharmas or biotechs, but it is the biggest spender. A free audio/video excerpt on big pharma licensing trends from Datamonitor Healthcare's webinar, "From R&D Investment To Externalization: Where Is The Pharma Industry Maximizing Value?"

Externalization is an important part of big pharma's business model. It is a key growth strategy that complements the investments these companies make in internal research & development. Big pharmas use deal-making to augment their pipelines and portfolios (through in-licensing), and conversely, to monetize non-core assets or to take advantage of unique external capabilities (through out-licensing).

Based on a review of licensing trends from 2012–16, big pharma companies have produced a significant amount of deals across various phases and therapy areas, with a high concentration at the early stages of development, and in oncology.

On May 23, Datamonitor Healthcare presented a webinar "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" Click below for the audio/video deep dive into big pharma licensing trends between 2012 and 2016.

Big Pharma Licensing Trends

[Click here to explore this interactive content online](#) ✎

Datamonitor Healthcare

For more information about Datamonitor Healthcare, [click here](#).